Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Angiopoietin-like 4

Angiopoietin-like 4

Brief Information

Name:Angiopoietin-related protein 4
Target Synonym:Angiopoietin-like protein 4,Hepatic fibrinogen/angiopoietin-related protein,HFARP,ARP4,PGAR,PP1158,PSEC0166,UNQ171/PRO197,Angiopoietin Like 4,Hepatic Fibrinogen/Angiopoietin-Related Protein,Angiopoietin-Related Protein 4,Pp1158,FIAF,NL2,Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Induced Angiopoietin-Related Protein,Hepatic Angiopoietin-Related Protein,PPARG Angiopoietin Related Protein,Fasting-Induced Adipose Factor,Angiopoietin-Like Protein 4,Angiopoietin-Like 4,UNQ171,TGQTL,HARP
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
AN4-H5243 Human Human Angiopoietin-like 4 / ANGPTL4 (166-406) Protein, His Tag
ACRO Quality

Synonym Name

ANGPTL4,ANGPTL2,ARP4,FIAF,HFARP,NL2,PGAR,pp1158,Angiopoietin like 4


Angiopoietin-related protein 4 (ANGPTL4) is also known as Hepatic fibrinogen / angiopoietin - related protein (HFARP), ARP4, PGAR. ANGPTL4 contains one fibrinogen C-terminal domain. ANGPTL4 is a homooligomer , and the homooligomer undergoes proteolytic processing to release its carboxyl fibrinogen-like domain, which circulates as a monomer. The homooligomer unprocessed form is able to interact with the extracellular matrix. ANGPTL4 may act as a regulator of angiogenesis and modulate tumorigenesis. ANGPTL4 inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage. ANGPTL4 may exert a protective function on endothelial cells through an endocrine action.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Lipisense Phase 1 Clinical Lipigon Pharmaceuticals AB, Secarna Pharmaceuticals GmbH & Co KG Hypertriglyceridemia Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message